Established in 2009, SpeeDx is a privately-owned company originating from Australia with headquarters in London and the United States, as well as distributors throughout Europe. SpeeDx specializes in advanced molecular diagnostic solutions that provide comprehensive information for enhanced patient care, surpassing mere detection capabilities. The company utilizes pioneering real-time polymerase chain reaction (qPCR) technology to deliver leading multiplex detection and priming strategies. Its product range is centered around multiplex diagnostics for sexually transmitted infections (STI), antibiotic resistance markers, and respiratory diseases.